Gemcitabine in epithelial ovarian cancer treatment: Current role and future perspectives

D. Lorusso, G. Ferrandina, E. Fruscella, L. Marini, V. Adamo, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review


Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown consistent activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogs, gemcitabine has been combined with carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of gemcitabine and other agents, including paclitaxel, is also feasible and has been actively studied in order to establish the role of gemcitabine in the management of treated and untreated ovarian cancer patients.

Original languageEnglish
Pages (from-to)1002-1013
Number of pages12
JournalInternational Journal of Gynecological Cancer
Issue number6
Publication statusPublished - Nov 2005


  • Gemcitabine
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Gemcitabine in epithelial ovarian cancer treatment: Current role and future perspectives'. Together they form a unique fingerprint.

Cite this